Thu, Dec 26, 2024
[Archive]
Volume 1, Issue 1 (11-2010)
Iran J Ped Hematol Oncol 2010, 1(1): 14-18 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Keikhaei B. Sequential Deferoxamine - Deferasirox in Treatment of Major Thalassemia with Iron Overload. Iran J Ped Hematol Oncol 2010; 1 (1) :14-18
URL: http://ijpho.ssu.ac.ir/article-1-24-en.html
URL: http://ijpho.ssu.ac.ir/article-1-24-en.html
Abstract: (7126 Views)
Abstract
Background
Iron overload is a major problem in patients with major thalassemia. An effective and safe iron chelator protocol with high compliance rate plays an important role in treatment of these patients. This study was done to assess the efficacy and safety of the sequential deferoxamine and deferasirox protocol in major thalassemia patients in Khuzestan province, Iran.
Material and Method
Sixty two patients were studied aged between 2 to 30 years old. A regimen consisted of 4 days deferasirox followed by 3 days deferoxamine. The duration of trial was 6 months. The efficacy was determined by comparison of ferritin level before and after treatment.
Results
Serum ferritin changed from 3590 ng/ml to 2563 ng /ml, which decreased significantly. During study 21% of patients experienced at least one side effect.
Conclusion
This is a new regimen with high efficacy, low toxicity and acceptable compliance.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
